<DOC>
	<DOC>NCT00055523</DOC>
	<brief_summary>Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)</brief_summary>
	<brief_title>A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion: Diagnosis of Crohn's disease CDAI score at baseline of between 220 and 450 Normal laboratory parameters Willing and able to give informed consent Exclusion: Diagnosis of ulcerative colitis Women cannot be pregnant or breastfeeding No previous use of infliximab or other antiTNF antagonists No previous history of tuberculosis or listeria infection No previous history of cancer other than successfully treated skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>